
EOLS
Evolus Inc.
$7.04
+$0.13(+1.88%)
57
Overall
40
Value
60
Tech
71
Quality
Market Cap
$452.44M
Volume
644.90K
52W Range
$5.71 - $17.12
Target Price
$19.40
Company Overview
| Mkt Cap | $452.44M | Price | $7.04 |
| Volume | 644.90K | Change | +1.88% |
| P/E Ratio | -9.0 | Open | $6.90 |
| Revenue | $266.3M | Prev Close | $6.91 |
| Net Income | $-50.4M | 52W Range | $5.71 - $17.12 |
| Div Yield | N/A | Target | $19.40 |
| Overall | 57 | Value | 40 |
| Quality | 71 | Technical | 60 |
No chart data available
About Evolus Inc.
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Latest News
Mizuho Securities Keeps Their Buy Rating on Evolus (EOLS)
TipRanks Auto-Generated Intelligence Newsdesk•3 days ago
Analysts Are Bullish on Top Healthcare Stocks: Evolus (EOLS), Inotiv (NOTV)
Catie Powers•12 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | EOLS | $7.04 | +1.9% | 644.90K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |